Prieto Esther, Vispe Eugenio, De Martino Alba, Idoipe Miriam, Rodrigo María J, Garcia-Martin Elena, Fraile José M, Polo-Llorens Vicente, Mayoral José A
Ophthalmology Department, Hospital Universitario Miguel Servet, Paseo Isabel la Católica 1-3, E-50009, Zaragoza, Spain.
Instituto de Investigación Sanitaria de Aragón (IIS-Aragón), Avda. San Juan Bosco 13, E-50009, Zaragoza, Spain.
Graefes Arch Clin Exp Ophthalmol. 2018 Mar;256(3):535-546. doi: 10.1007/s00417-017-3893-5. Epub 2018 Jan 20.
To study the safety and biocompatibility of Laponite clay (LAP) within an intravitreal and suprachoroidal administration in rabbit eyes.
Thirty-two New Zealand albino rabbits were divided into two experimental groups to test intravitreal (IVT group) and suprachoroidal (SCS group) administration of a 100-μl and 50-μl Laponite suspension respectively. Following injection, the eyes were monitored by ocular tonometry, slit-lamp eye examination and indirect ophthalmoscopy, at 24 h, 1, 4, 12, and 14 weeks post administration. Histological examination was also performed to determine whether any ocular pathological change had occurred. Throughout the study, LAP presence in vitreous was estimated by complexometric titration with ethylenediaminetetraacetic acid (EDTA), taking advantage of the Laponite high content of magnesium ions.
Neither significant differences in the intraocular pressure, nor relevant ocular complications were found in the two experimental groups after LAP administration. The histology of the retina remained unchanged. LAP presence in vitreous could be indirectly confirmed by complexometric titration until 14 weeks post administration in eyes of IVT group.
Laponite could be considered as a vehicle for potential clinical use in ocular drug administration, due to its proven ocular biocompatibility and its transparency in gel state.
研究锂皂石粘土（LAP）在兔眼玻璃体内和脉络膜上腔给药的安全性和生物相容性。
将32只新西兰白化兔分为两个实验组，分别测试玻璃体内（IVT组）和脉络膜上腔（SCS组）注射100μl和50μl锂皂石悬浮液。注射后，在给药后24小时、1周、4周、12周和14周通过眼压测量、裂隙灯眼部检查和间接检眼镜对眼睛进行监测。还进行了组织学检查以确定是否发生任何眼部病理变化。在整个研究过程中，利用锂皂石中高含量的镁离子，通过乙二胺四乙酸（EDTA）络合滴定法估计玻璃体内锂皂石的存在情况。
在给予锂皂石后，两个实验组的眼压均无显著差异，也未发现相关眼部并发症。视网膜组织学保持不变。在IVT组的眼中，直到给药后14周，通过络合滴定法可间接确认玻璃体内锂皂石的存在。
锂皂石因其已证实的眼部生物相容性及其凝胶状态下的透明度，可被视为眼部药物给药潜在临床应用的载体。
